Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 14.4% in December

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 952,300 shares, an increase of 14.4% from the December 15th total of 832,200 shares. Based on an average daily volume of 94,200 shares, the short-interest ratio is currently 10.1 days. Approximately 4.4% of the company’s stock are sold short.

Insider Transactions at Gyre Therapeutics

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the sale, the president now directly owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders sold 16,054 shares of company stock valued at $185,897. Insiders own 19.52% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares during the last quarter. State Street Corp lifted its stake in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares during the last quarter. Advantage Alpha Capital Partners LP purchased a new stake in Gyre Therapeutics during the third quarter worth approximately $334,000. Finally, WINTON GROUP Ltd purchased a new stake in Gyre Therapeutics during the second quarter worth approximately $220,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Trading Up 1.4 %

Shares of NASDAQ:GYRE traded up $0.15 on Friday, hitting $10.95. 48,956 shares of the company’s stock were exchanged, compared to its average volume of 116,811. Gyre Therapeutics has a 1-year low of $8.26 and a 1-year high of $26.37. The firm’s 50-day moving average is $11.57 and its 200 day moving average is $12.64.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.